Precision BioSciences (NASDAQ:DTIL – Get Free Report) and Upstream Bio (NASDAQ:UPB – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.
Volatility & Risk
Precision BioSciences has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Upstream Bio has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500.
Institutional & Insider Ownership
38.0% of Precision BioSciences shares are owned by institutional investors. 4.5% of Precision BioSciences shares are owned by insiders. Comparatively, 13.6% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Precision BioSciences | 1 | 0 | 2 | 0 | 2.33 |
| Upstream Bio | 1 | 0 | 3 | 0 | 2.50 |
Precision BioSciences currently has a consensus price target of $47.00, suggesting a potential upside of 841.88%. Upstream Bio has a consensus price target of $43.33, suggesting a potential upside of 59.67%. Given Precision BioSciences’ higher probable upside, analysts plainly believe Precision BioSciences is more favorable than Upstream Bio.
Profitability
This table compares Precision BioSciences and Upstream Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Precision BioSciences | -11,977.36% | -233.77% | -78.93% |
| Upstream Bio | -4,366.77% | -28.71% | -27.94% |
Valuation & Earnings
This table compares Precision BioSciences and Upstream Bio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Precision BioSciences | $68.70 million | 0.96 | $7.17 million | ($8.40) | -0.59 |
| Upstream Bio | $2.37 million | 618.84 | -$62.81 million | ($1.88) | -14.44 |
Precision BioSciences has higher revenue and earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.
Summary
Upstream Bio beats Precision BioSciences on 9 of the 14 factors compared between the two stocks.
About Precision BioSciences
Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
About Upstream Bio
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
